The findings suggest that targeting this pathway could help limit damage to healthy lung tissue during cancer radiotherapy, although the approach has not been tested as a treatment in patients. The study appeared in Nature Communications on October 20, 2026, under the title “Type I IFN promotes ILC2-to-ILC1 plasticity in pre-clinical radiation-induced lung injury.” Radiation can be lifesaving in cancer treatment, but healthy lung tissue exposed during radiotherapy may develop severe and lasting damage.

City of Hope reported that as many as 70% of people diagnosed with lung cancer undergo radiation at some point in their treatment. Following injury, as many as 20% of patients may experience debilitating breathing difficulties and reduced quality of life, with some becoming dependent on supplemental oxygen. The new study does not establish that blocking interferon-beta can prevent these outcomes in people.

Instead, it identifies a cellular and molecular mechanism in a mouse model of radiation-induced lung injury and shows that interrupting the pathway can lessen pulmonary damage in experimental animals. Corresponding author Heather McGee, M.D., Ph.D., an assistant professor in City of Hope’s departments of radiation oncology and immuno-oncology, led the investigation with first author Jaeho Kim, M.D., Ph.D., a radiation oncology postdoctoral fellow. The team developed a mouse model of radiation injury to the lung and used immune-cell tracking methods to examine how radiation changed innate lymphoid cells, or ILCs.

These comparatively rare immune cells were the focus because the researchers wanted to determine whether they changed identity or function after irradiation. The experiments addressed three linked questions: whether radiation altered the ILC population, which signal drove the alteration, and whether blocking that signal could reduce lung damage. The first result was a pronounced transformation within the innate lymphoid cell population.

ILC2 cells normally help protect the lung from damage, whereas ILC1 cells promote inflammation that can injure healthy tissue. After radiation exposure, the investigators observed ILC2 cells adopt characteristics associated with the inflammatory ILC1 state. They described this transition as ILC2-to-ILC1 plasticity, meaning that the cells did not simply remain in one functional identity but changed their state in response to radiation.

The altered cells were linked to harmful inflammation in the lung. This result extends the study’s focus beyond better-known immune cells, including T cells, and points to a specific population through which radiation can affect lung tissue. The second finding identified interferon-beta as the molecular signal driving the transition.

Radiation increased levels of this type I interferon signaling protein, while experimental disruption of its pathway reduced the shift of ILC2 cells toward the inflammatory ILC1 state. McGee described the mechanism as comparable to a player switching teams: radiation-induced interferon-beta could move innate lymphoid cells away from a protective role and toward one that promotes inflammation. The finding provides a mechanistic link rather than only an association.

In the experimental system, a defined signaling event was connected to a change in cellular identity and function, and that function was connected to damage in healthy lung tissue. The researchers also examined human innate lymphoid cells to determine whether the biological changes seen in the mouse model had a counterpart in human cells. Those experiments produced similar changes, indicating that the reprogramming mechanism was not confined to the mouse cells used for the lung-injury experiments.

Human-cell findings support biological relevance, but they do not demonstrate that modifying interferon-beta signaling will be safe or effective in patients receiving radiation. The source described the pathway intervention as a potential strategy, and no human treatment trial or clinical efficacy result was reported. Its effects on radiation-related lung injury therefore remain a preclinical possibility rather than an established clinical application.

For the third set of experiments, the team tested whether blocking interferon-beta signaling during radiation could protect the lungs. In mice, disrupting the pathway reduced inflammation, limited lung injury and decreased fibrosis, the scarring process that can permanently damage healthy lung tissue. These outcomes were measured in an experimental model of radiation-induced pulmonary injury, not among people with cancer.

The result nevertheless identifies a focused point of intervention. That distinction is central to the study’s proposal: the biological pathway associated with lung harm was interrupted while radiation was being delivered. The clinical importance of the work lies in the potentially persistent consequences of radiation injury.

Healthy lung tissue exposed during radiotherapy can become inflamed and scarred, leading to breathing difficulty, reduced quality of life and limits on future cancer treatment options. City of Hope noted that some affected patients become tethered to heavy oxygen tanks. Kim said the findings suggest that high levels of interferon-beta contribute to radiation-induced lung damage and that blocking the signaling pathway could offer a potential way to reduce this side effect.

If the approach proves effective in people, it could protect lung tissue and perhaps expand radiation options for people with chronic lung conditions such as chronic obstructive pulmonary disease, or allow more aggressive radiation treatment when needed. Those possibilities remain conditional and untested. The researchers did not merely document inflammation and lung damage after irradiation.

They showed that innate lymphoid cells changed state, identified increased interferon-beta signaling as the driver of that change, observed related biological changes in human ILCs, and found that disrupting the pathway reduced inflammation, injury and fibrosis in mice. The design supports the conclusion that interferon-beta signaling contributes causally to radiation-associated lung damage within the experimental model. It does not establish how the same pathway behaves in the full complexity of a person receiving cancer treatment, nor whether targeted blockade could produce benefits without other immune effects.

City of Hope, which described the work as a potential route to new treatments that protect healthy lung tissue, is part of a broader cancer research and treatment organization. The project was funded by grants from the National Cancer Institute, the National Institutes of Health and the Veterans Affairs Office of Research and Development. The release stated that its content was solely the responsibility of the authors and did not necessarily represent the official views of the NIH.

Because the investigation is preclinical, the result should not be interpreted as evidence of a clinical therapy. What it establishes is a testable mechanism: radiation-induced interferon-beta signaling appears to convert lung-protective ILC2 cells into inflammatory ILC1 cells, and interrupting that pathway reduced radiation-related lung harm in mice. Whether the same selective strategy can safely and effectively translate to human radiotherapy remains to be established.

Subject of Research: Preclinical research on interferon-beta-driven immune-cell reprogramming in radiation-induced lung injury

Article Title: New study identifies immune trigger behind radiation-related lung damage

Article References: New study identifies immune trigger behind radiation-related lung damage. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: radiation-induced lung injury, interferon-beta, innate lymphoid cells, ILC2-to-ILC1 plasticity, pulmonary fibrosis, radiotherapy, lung inflammation, cancer treatment, identifies, immune, trigger, behind

The study, led by Fariya Khan and colleagues at the Stem Cell Research Centre of the Department of Hematology at Sanjay Gandhi Postgraduate Institute of Medical Sciences in Lucknow, together with investigators at the ICMR-National Institute for Research in Environmental Health in Bhopal, set out to address a conspicuous gap in the toxicological literature. Although phthalates are absorbed primarily through ingestion, skin contact and inhalation, and although population studies have repeatedly linked phthalate burdens to reduced lung function, asthma exacerbation and respiratory morbidity, direct experimental data on how dimethyl phthalate, commonly abbreviated DMP, injures lung tissue have remained scarce. Because inhalation is a major route of human exposure, the team chose to model the lung’s first line of contact with inhaled pollutants: the alveolar epithelial barrier.

To do this, the researchers used A549 cells, a human lung adenocarcinoma-derived cell line that behaves much like the type II alveolar epithelial cells lining the air sacs of the lung. These cells form a critical defensive barrier between the outside world and the bloodstream, and their dysfunction is a well-recognized harbinger of chronic airway disease. The investigators exposed the cells to a range of DMP concentrations over varying durations, then interrogated the cells with a battery of complementary techniques designed to capture different dimensions of cellular injury.

The results were striking. Under phase-contrast microscopy, exposed cells displayed visible morphological deterioration, rounding and detaching as the chemical’s concentration and the length of exposure increased. Cell viability, measured with the MTT assay, an established colorimetric test that gauges the metabolic activity of living cells, declined in a clear dose- and time-dependent fashion. In practical terms, the more DMP the cells encountered and the longer they endured it, the fewer of them survived. The pattern of cell death mattered as much as its extent. Flow cytometric analysis using Annexin V and propidium iodide staining, a method that distinguishes the orderly programmed death known as apoptosis from the messier rupture of necrosis, indicated that DMP drove the cells predominantly toward necrotic death. Necrosis is significant in the lung because it releases intracellular contents that can further inflame surrounding tissue, potentially amplifying injury well beyond the cells that are directly killed.

Behind that cytotoxicity, the study found, lay a burst of oxidative stress. Using DCFH-DA, a fluorescent probe that lights up in the presence of intracellular reactive oxygen species, and MitoSOX, a dye engineered to report specifically on superoxide generation inside mitochondria, the team documented a substantial rise in both general cellular oxidants and mitochondrial superoxide. This distinction is technically important. Mitochondria are not merely cellular power plants; in lung biology they act as signaling hubs whose dysfunction can tip cells toward inflammation and death. When the electron transport chain is perturbed, superoxide accumulates, membranes are peroxidized and the cell’s redox balance collapses. The DMP-exposed cells showed precisely this mitochondrial signature, suggesting that the chemical attacks the energy-producing machinery of alveolar epithelium rather than simply poisoning the cell membrane from outside.

Oxidative stress, in turn, is a recognized trigger for inflammatory signaling. Reactive oxygen species activate transcription factors such as nuclear factor kappa B, or NF-κB, which switches on genes encoding pro-inflammatory cytokines. That is exactly what the researchers observed at the molecular level. Quantitative real-time PCR, which measures messenger RNA abundance, revealed significantly elevated expression of tumor necrosis factor alpha, interleukin-6 and interleukin-8 in DMP-treated cells. Enzyme-linked immunosorbent assays confirmed that at least two of these cytokines, IL-6 and IL-8, were secreted in greater quantities into the surrounding medium, meaning the injured cells were actively broadcasting inflammatory signals to their environment rather than merely harboring them internally.

The cytokine triad identified in this study is not arbitrary. TNF-α, IL-6 and IL-8 are among the signature inflammatory mediators detected in the sputum and airways of patients with COPD, a progressive lung disease that ranks among the leading causes of death worldwide and is characterized by persistent airflow limitation, chronic inflammation and irreversible structural remodeling of the small airways. IL-8 in particular acts as a chemoattractant that recruits neutrophils into the lung, while IL-6 sustains systemic and local inflammatory loops. The fact that a common consumer chemical can coax lung epithelial cells toward this same inflammatory program, without any virus, smoke or allergen present, is the finding most likely to trouble environmental health researchers.

Perhaps the most provocative result concerns fibronectin. This high-molecular-weight glycoprotein is a scaffold component of the extracellular matrix, and its accumulation is a hallmark of tissue remodeling and fibrosis. The study found that DMP exposure enhanced both the expression and the extracellular accumulation of fibronectin in the A549 cultures, as assessed by RT-qPCR, ELISA and immunocytochemistry. In the context of chronic lung disease, small-airway fibrosis driven by aberrant epithelial-mesenchymal crosstalk is considered a key structural lesion that fixes airflow obstruction in place. Epithelial cells that are injured or stressed can transition toward a mesenchymal-like phenotype and deposit matrix proteins, thickening the airway wall and stiffening the tissue. The DMP-induced fibronectin buildup observed in vitro therefore hints at a plausible mechanism by which chronic phthalate inhalation could contribute to the remodeling responses implicated in COPD, although the authors are careful to frame this as overlap with disease pathways rather than proof of causation.

The epidemiological backdrop gives these cellular findings added weight. Analyses of large national survey cohorts, including NHANES data from 2007 to 2012, have associated higher phthalate exposure with reduced pulmonary function in adults, and urinary phthalate metabolite mixtures have been linked to diminished lung function in adolescents. Randomized human exposure work with dibutyl phthalate, a chemically related ester, has shown that inhalation exposure can worsen allergen-induced declines in lung function and alter airway immunology. Phthalates are also semi-volatile and abundantly present in house dust, meaning indoor air can carry measurable concentrations, and infants and children may face especially high exposure in their homes. Meanwhile, dimethyl phthalate has been shown to permeate human skin in laboratory models, adding a dermal route to the inhalation and dietary pathways that already concern exposure scientists.

What makes DMP particularly vexing from a regulatory standpoint is its dual identity as a low-molecular-weight phthalate that is not classified in the same restricted category as the better-studied di(2-ethylhexyl) phthalate, yet is arguably more volatile and therefore more available for inhalation. It is formulated into insect repellents, applied in lacquers and coatings, and released from consumer goods into indoor air. The new study’s demonstration that it kills alveolar epithelial cells, floods them with mitochondrial superoxide, provokes a COPD-like cytokine profile and drives fibronectin deposition collectively sketches a coherent mechanism of pulmonary harm: chemical insult, oxidant generation, inflammatory amplification and matrix remodeling.

The researchers caution that their work is an in vitro investigation, conducted on a cancer-derived cell line at concentrations and durations that do not translate directly to real-world exposure scenarios. A549 cells, while a standard and widely used model of the alveolar epithelium, cannot reproduce the full complexity of lung tissue, the immune system or the metabolic processing of phthalates in the body. Nevertheless, the concordance between the pathways activated in these cultures and those documented in COPD patients lends biological plausibility to the epidemiological associations that have accumulated over the past two decades.

The study was supported by the Science and Engineering Research Board of the Department of Science and Technology, Government of India, under grant EEQ/2022/000034, and by a DST INSPIRE fellowship. As phthalates continue to accumulate in indoor environments and as COPD’s global burden grows, the authors argue that their findings underscore the need to treat inhalation exposure to dimethyl phthalate as a legitimate respiratory health risk, one that deserves the same regulatory scrutiny that other members of the phthalate family have begun to receive.